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The carotid bodies (CB) are peripheral chemoreceptors that sense changes in arterial
blood O2, CO2, and pH levels. Hypoxia, hypercapnia, and acidosis activate the CB, which
respond by increasing the action potential frequency in their sensory nerve, the carotid
sinus nerve (CSN). CSN activity is integrated in the brain stem to induce a panoply
of cardiorespiratory reflexes aimed, primarily, to normalize the altered blood gases, via
hyperventilation, and to regulate blood pressure and cardiac performance, via sympathetic
nervous system (SNS) activation. Besides its role in the cardiorespiratory control the CB
has been proposed as a metabolic sensor implicated in the control of energy homeostasis
and, more recently, in the regulation of whole body insulin sensitivity. Hypercaloric diets
cause CB overactivation in rats, which seems to be at the origin of the development
of insulin resistance and hypertension, core features of metabolic syndrome and type
2 diabetes. Consistent with this notion, CB sensory denervation prevents metabolic and
hemodynamic alterations in hypercaloric feed animal. Obstructive sleep apnea (OSA) is
another chronic disorder characterized by increased CB activity and intimately related
with several metabolic and cardiovascular abnormalities. In this manuscript we review
in a concise manner the putative pathways linking CB chemoreceptors deregulation with
the pathogenesis of insulin resistance and arterial hypertension. Also, the link between
chronic intermittent hypoxia (CIH) and insulin resistance is discussed. Then, a final section
is devoted to debate strategies to reduce CB activity and its use for prevention and
therapeutics of metabolic diseases with an emphasis on new exciting research in the
modulation of bioelectronic signals, likely to be central in the future.
Keywords: carotid body, chronic intermittent hypoxia, insulin resistance, metabolic dysfunction, obstructive sleep
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THE CAROTID BODIES
The carotid bodies (CB) are peripheral chemoreceptors located
bilaterally in the bifurcation of the common carotid artery
that classically sense changes in arterial blood such as low O2
(hypoxia), high CO2 (hypercapnia), and low pH (acidosis).
Hypoxia and acidosis/hypercapnia activate the CB, inducing an
increase in the frequency of discharge in the nerve endings of
its sensorial nerve, the carotid sinus nerve (CSN). The CSN
activity is integrated in the nucleus solitary tract to induce a myr-
iad of respiratory reflexes aimed to normalize the altered blood
gases, via hyperventilation (Gonzalez et al., 1994), and to regu-
late blood pressure and cardiac performance via an increase in
the activity of the sympathetic branch of the autonomic nervous
system (SNS) (Marshall, 1994) (see Figure 1). The chemorecep-
tor cells, also known as glomus or type I cells, are the main
cellular constituent of the CB and are generally accepted as its
chemosensory unit. These cells, which are derived of the neural
crest, contain several classical neurotransmitters including, cat-
echolamines [CA; dopamine (DA), and norepinephrine (NE)],
serotonin, ACh, neuropeptides (substance P and enkephalins)
and adenosine (Ado) and ATP (Gonzalez et al., 1994; Zhang et al.,
2000; Rong et al., 2003; Buttigieg and Nurse, 2004; Conde and
Monteiro, 2004; Conde et al., 2012a). All these substances, their
agonists and antagonists are capable of modifying, inhibiting or
stimulating CSN activity. In addition to chemoreceptor cells, the
CB also possesses type II cells, or sustentacular cells and it has
been proposed that they are adult neural stem cells sustaining
neurogenesis in vivo in response to physiological stimuli, like
chronic hypoxia, and acting in paracrine signaling during hypoxia
(Pardal et al., 2007; Piskuric and Nurse, 2013).
ROLE OF CAROTID BODY IN METABOLISM
EVIDENCES FOR A ROLE OF CAROTID BODY IN GLUCOSE
HOMEOSTASIS
The idea of a physiological role of the CB on the control of glu-
cose metabolism was first suggested by Petropavlovskaya in the
50’s. In this pioneer study it was shown that the stimulation of
the CB induces a reflex hyperglycemia, an effect that is mediated
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FIGURE 1 | Schematic representation of the chemoreflexes elicited by the carotid bodies. (A) Representation of important mechanism involved in the
reflex-responses elicited by the carotid body. (B) Stimulation of the carotid body is capable of produce cardiovascular, respiratory, endocrine, and renal responses.
by the adrenal medulla, since it was not observed in adrenalec-
tomized animals (Petropavlovskaya, 1953). Twenty five years later,
Alvarez-Buylla and de Alvarez-Buylla (1988) confirmed those
results by demonstrating that the pharmacological stimulation of
the CB with cyanide (NaCN) produced an increase in hepatic glu-
cose output in cats, this reflex response being eliminated by bilat-
eral adrenalectomy or by surgical removal of the neurohypophysis
(Alvarez-Buylla et al., 1997). Also, it was shown that changes in
blood concentration in the CB-CSN, superfused in vivo, modify
brain glucose retention, suggesting that chemosensory activity in
the CSN controls brain glucose metabolism (Alvarez-Buylla and
de Alvarez-Buylla, 1994). In parallel with the increase in hepatic
glucose output, one would expect an increase in plasma insulin
levels to ensure an adequate glucose utilization by the peripheral
tissues and, in fact, stimulation of CBs by corconium, a nicoti-
nomimetic agent, caused a rise in circulating insulin that was
reversed by CSN resection (Anichkov and Tomilina, 1962). Later
on, Koyama et al. (2000) demonstrated that CB plays an impor-
tant role in glucose homeostasis in vivo, since dogs that have their
CB resected presented lower arterial glucagon in basal conditions
and reduced glucagon and cortisol levels during insulin-induced
hypoglycemia, together with a marked decrease in endogenous
hepatic glucose production in response to hypoglycemia, and
with an increase in insulin sensitivity, independent of blood glu-
cose level. These last results suggested for the first time that CB
resection affects the response to moderate hyperinsulinemia and
therefore, that the CB may play a role in glucose homeostasis that
is not related with the hypoglycemic counterregulatory response.
The results obtained by Koyama et al. (2000) were sup-
ported by clinical studies where it was demonstrated that, the
rate of glucose infusion necessary to maintain glucose levels in
a hyperinsulinemic-hypoglycemic clamp was significantly higher
during hyperoxia than in normoxia (Wehrwein et al., 2010). In
the same study, the authors also observed that hyperoxia, which
blunts CB activity, decreased the release of counter-regulatory
hormones such as adrenaline, cortisol, glucagon and growth
hormone, which seems to indicate that the CB play an impor-
tant role in neuroendocrine responses during hypoglycemia
(Wehrwein et al., 2010). However, the absence of adequate con-
trols in hyperinsulinemic-euglycemic conditions in this study
does not allow assigning the effects to the hyperinsulinemia per
se or to hypoglycemia. In another clinical study designed to
determine whether hypo- and hyperglycaemia modulate the ven-
tilatory responses to hypoxia, it was shown that hypoglycemia, as
well as hyperglycemia, produced an increase in ventilation and
in the hypoxic ventilatory response, being the latter accompanied
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by an increase in circulating counter-regulatory hormones (Ward
et al., 2007). Interestingly, both hypo- and hyperglycemia were
obtained under hyperinsulinemic conditions, and therefore it
is possible that the effect in ventilation observed was due to
hyperinsulinemia rather than to altered glucose concentrations.
More recently, our laboratory has shown that CBs are overac-
tivated in diet-induced animal models of insulin resistance and
hypertension (Ribeiro et al., 2013). Also, we have demonstrated
that insulin resistance and hypertension produced by hyper-
caloric diets are completely prevented by chronic bilateral CSN
resection, and these results strengthen the link between CB dys-
function and the development of insulin resistance (Ribeiro et al.,
2013). In addition, we observed that CSN resection in control
animals decreased insulin sensitivity, suggesting that CB also con-
tributes to maintain metabolic control in physiological conditions
(Ribeiro et al., 2013). Therefore, the research in the field per-
formed since Petropavlovskaya work in the early 1950’s strongly
supports that the CB is a key organ in glucose homeostasis and
that its dysfunction contributes to the pathogenesis of metabolic
disturbances.
GLUCOSE SENSING IN THE CAROTID BODY
One of the hypotheses that came out to explain the role of the
CB in glucose homeostasis was the potential of the CB as a glu-
cosensor. Whereas some in vivo and in vitro studies, performed
in cultured CB chemoreceptor cells or slices, had shown that
CB could respond to blood glucose levels, (Koyama et al., 2000;
Pardal and Lopez-Barneo, 2002; Zhang et al., 2007) others have
completely denied a direct involvement of the CB in glucose sens-
ing (Almaraz et al., 1984; Bin-Jaliah et al., 2004, 2005; Conde
et al., 2007; Fitzgerald et al., 2009; Gallego-Martin et al., 2012).
Due to these controversial results, the sensitivity of the CB to
hypoglycaemia is still a hot topic in the CB field.
In cultured CB slices, perfusion with low or glucose-free
solutions at a PO2 ≈150 mmHg produced an increase in CAs
release from chemoreceptor cells with a magnitude compara-
ble to the response evoked by hypoxia and potentiated hypoxic
responses (Pardal and Lopez-Barneo, 2002). Moreover it was
found that low glucose inhibited K+ currents (Pardal and Lopez-
Barneo, 2002) in an extent similar to the observed by Peers
during intense hypoxia (Peers, 1990); low glucose also promoted
Ca2+ entry in chemoreceptor cells (Pardal and Lopez-Barneo,
2002). Lopez-Barneo’s group published that sensitivity to low
glucose and to hypoxia depends on different signal transduction
mechanisms, although they converge on the final steps causing
transmembrane Ca2+ influx and transmitter release (García-
Fernández et al., 2007). Almost at the same time, but using an
experimental model of co-culture of type I clusters and afferent
petrosal neurons, Zhang et al. (2007) described that low glu-
cose increased the spiking activity in the neurons, this increase
being sensitive to purinergic and nicotinic blockers, implying
that low glucose stimulates chemoreceptor cells and promotes
the release of ATP and ACh. Contrasting with these results,
CSN activity in freshly isolated cat and rat CB–CSN prepara-
tion was not modified by perfusion with glucose-free or low-
glucose solutions (Almaraz et al., 1984; Bin-Jaliah et al., 2004,
2005). Also, Conde et al. (2007) demonstrated that low glucose
concentrations neither activate the release of neurotransmit-
ters, namely CAs and ATP, from the CB, nor altered basal and
hypoxia (5% O2)-induced CSN action potential frequency in
freshly isolated whole CB preparations (Conde et al., 2007). In
the same line, Fitzgerald et al. (2009) showed that the release
of ATP from the cat CB was not modified in the presence of
hypoglycemia but, surprisingly, they observed an increase in
the release of ACh in the same conditions (Fitzgerald et al.,
2009). Additionally, it was shown that withdrawal of glucose from
the perfusion media did not activate the KATP channels, sug-
gesting that this channel was insensitive to hypoglycemia (Kim
et al., 2011). Altogether these results suggest that low glucose
is not a direct stimulus for the CB chemoreceptors and do not
support a significant physiological role of the CB as a glucose
sensor.
Several differences can account for these discrepant results
regarding glucose sensing in the CB, namely species differences,
different dissociation protocols or culture conditions that lead
to an altered cells phenotype, as suggested by Kumar (2007), or
even the differences in the PO2 levels used by some authors, as
postulated by Zhang et al. (2007). However, Conde et al. (2007)
have shown in the whole CB that low or absent glucose does
not activate either chemoreceptor cells or the CB–CSN complex
at different PO2 tested in a very wide range (∼133, 66, 46, and
33 mmHg) and thus, differences in the PO2 used in the exper-
iments in intact preparations vs. slices or co-cultures is not the
factor determining divergent findings, as suggested by Zhang
et al. (2007). More recently, Gallego-Martin et al. (2012) demon-
strated that in intact CBs cultured during 1 day, but not in freshly
isolated organs, 0 mM glucose media potentiates the release of
CAs elicited by hypoxia and that chemoreceptor cells in cul-
ture become transiently more dependent on glycolysis suggesting
that the scarcity of glucose leads the cells to acquire the abil-
ity to increase their neurosecretory response to hypoxia. Another
relevant issue in the discussion is the duration of glucose depri-
vation. While glucose reduction or deprivation did not have an
effect when applied for short periods of time (<15 min), either
in basal conditions or in response to hypoxia, when applied
for longer periods of time (up to 120 min) it caused a sponta-
neous increase in basal release of CAs observable after 40 min
of glucose deprivation. Concomitantly, bursts of CSN activity
were observed with a comparable time course to the release of
CAs, that culminated in a complete loss of the capacity of the
CSN to respond to hypoxia (Conde et al., 2007). Consistent with
these findings Holmes et al. (2014) have recently demonstrated
that basal CSN activity was sustained during glucose deprivation
approximately for 30 min before irreversible failure following a
brief period of increased activity. Also, they showed that phar-
macological inhibition of glycogenolysis and depletion of glyco-
gen reduced the time to glycolytic run down, suggesting that
glycogen metabolism in chemoreceptor cells allows glycogenol-
ysis and the maintenance of CSN basal activity during hypo-
glycemia (Holmes et al., 2014). Therefore, glycogen metabolism
may account for the differences reported in the capacity of the
CB to sense glycemia and could contribute to CB responses in
pathological conditions associated with an overstimulation of
the organ.
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IS INSULIN A STIMULUS FOR CB ACTIVATION?
A large body of literature supports a role for the central nervous
system in insulin-induced sympathoexcitation, as the injection
of insulin on arcuate nucleus and paraventricular nucleus has
been shown to produce an increase in spinal sympathetic out-
flow, mediated by dorsal hypothalamus and rostral ventrolateral
medulla (for a review see Dampney, 2011). However, this effect
cannot be exclusively assigned to a centrally-mediated mecha-
nism, since the injection of insulin into the carotid artery of
anesthetized dogs produces an increase in blood pressure and
sympathetic activity higher than the systemic insulin administra-
tion, being the effect abolished by ganglionic blockade (Pereda
et al., 1962). These results were the first to suggest a role for
the peripheral nervous system in insulin-mediated sympathetic
activity. During the evaluation of a putative direct role of the CB
in glucose sensing, Bin-Jaliah et al. (2004) observed that insulin
infusion, used to produce hypoglycemia, increased minute venti-
lation and the rate of O2 consumption (VO2), an effect that was
totally mediated by the CB, since CSN denervation blunted it.
The same authors demonstrated afterwards that insulin-induced
hypoglycemia was associated with a significantly increase in CO2
chemosensitivity, an effect that was mediated by the CB, since the
effect was lost in animals that had their CSN resected (Bin-Jaliah
et al., 2005). Since in vitro hypoglycemia was incapable of mod-
ifying basal CSN activity (Bin-Jaliah et al., 2004; Conde et al.,
2007) and blunted the response of CSN to hypercapnia (Bin-
Jaliah et al., 2005) the elevation of ventilation observed in vivo
by Bin-Jaliah’s group was somehow surprising (Bin-Jaliah et al.,
2004, 2005) and the hypothesis of being an indirect consequence
of systemic hypoglycemia related to some other undetermined
substance had to be considered. To pursue this hypothesis, our
group has been dedicated to investigate whether insulin itself is
capable of stimulating the CB and of eliciting a neurosecretory
response. We have demonstrated the presence of insulin recep-
tors in the rat CB by western-blot and its phosphorylation in
response to insulin (Ribeiro et al., 2013). The presence of insulin
receptors was also confirmed on finding that isolated whole CBs
incubated with insulin accumulate more 2-deoxiglucose than the
diaphragm muscle (Gallego Martin et al., 2014). Insulin is also
capable to induce a rise in intracellular Ca2+ in chemorecep-
tor cells and to elicit the release of ATP and dopamine from the
whole CB in a concentration-dependent manner (Ribeiro et al.,
2013). As schematically represented in Figure 2, we have also
shown that this neurosecretory response is transduced into an
increase in ventilation in the whole animal, as insulin increased
the spontaneous ventilation in a dose-dependent manner during
an euglycemic clamp (Ribeiro et al., 2013). The increase in venti-
lation induced by insulin is mediated by the CB, since it is absent
in animals that had their CSN resected (Ribeiro et al., 2013).
Contrarily to our results, Bin-Jaliah et al. (2004) proposed that
the ventilatory and metabolic effects observed in vivo were not
due to insulin per se, since the increase in ventilation produced by
insulin was absent during an euglycemic clamp. However, some
differences in the methodology used can be in the basis of these
discrepancies. In our study we have administrated a bolus of
insulin intracarotidally to guarantee that the first site of insulin
action is the CB, and not systemically as Bin-Jaliah et al. (2004,
2005). Also we performed a dose-response curve in which several
concentrations of insulin were tested, making the results more
robust in terms of concluding on a role of insulin in CB mod-
ulation. In fact, the neurosecretory response and the increase in
ventilation elicited by insulin in our experimental setting support
the idea that insulin is a very powerful stimulus for CB activa-
tion. Nevertheless, these findings do not exclude that the central
nervous system is also involved in the sympathetic activation
observed in response to circulating insulin and more studies are
required to clarify the exact contribution of both the peripheral
and the central nervous system in this process. It is undoubt-
edly however, that the overactivation of the SNS, measured as the
increase in plasmatic CAs (norepinephrine + epinephrine) and
in CAs (norepinephrine + epinephrine) content of the adrenal
medulla (Figure 3) and the insulin resistance (Figure 4) seen in
hypercaloric animal models are prevented by surgical resection of
the CSN. These findings point toward a new role for the CB in the
regulation of peripheral insulin sensitivity and in the pathogenesis
of insulin resistance (Ribeiro et al., 2013).
FIGURE 2 | Schematic representation of insulin action in the carotid
body. Insulin will act on insulin receptors present in the carotid body
chemoreceptor cells eliciting an increase in intracellular Ca2+ and the release
of neurotransmitters, such as dopamine and ATP. The insulin-induced
neurosecretory response in chemoreceptor cells is transduced in an increase
in ventilation and in an augmented sympathetic outflow.
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FIGURE 3 | Effect of carotid sinus nerve resection on sympathetic
nervous system activity, measured as circulating catecholamines
[norepinephrine (NE) + epinephrine (Epi)] (A) and adrenal medulla
catecholamines (NE + Epi) content (B), in control, high fat (HF) and high
sucrose (HSu) diet rats. Bars represent mean ± s.e.m. Two-Way ANOVA
with Bonferroni multicomparison tests; ∗p < 0.05, ∗∗∗p < 0.001 vs. control;
#p < 0.05, ##p < 0.01, ###p < 0.001 vs. values within the same group
(adapted from Ribeiro et al., 2013).
FIGURE 4 | Representative excursion curves for the insulin tolerance
test in control (A), high fat (HF) (B), and high fat animals submitted
to carotid sinus nerve resection (C) rats. Note that insulin sensitivity,
expressed by the constant of the insulin tolerance test (KITT) decrease in
the HF animals, this decrease being completely prevented by the bilateral
resection of the carotid sinus nerve. HF animals were achieved by
submitting the animals to a HF diet (45% lipid-rich diet) during 21 days.
Bilateral resection of the carotid sinus nerve (C) was performed 5 days
prior to submitting the animals to HF diet (adapted from Ribeiro et al.,
2013).
LINKING INSULIN, SYMPATHETIC NERVOUS SYSTEM
ACTIVATION AND METABOLIC DYSFUNCTION: THE ROLE OF
THE CAROTID BODY
The sympathetic nervous system (SNS) is an important compo-
nent of the autonomic nervous system playing a major role in
the maintenance of homeostasis due to its involvement in the
control of the cardiovascular system and of several metabolic pro-
cesses. Sympathetic overactivity has been associated with several
diseases, such as cardiovascular diseases (Graham et al., 2004),
kidney disease (Converse et al., 1992), and metabolic distur-
bances, including type 2 diabetes (Huggett et al., 2003; Grassi
et al., 2005, 2007; Kobayashi et al., 2010). In metabolic diseases the
increase in sympathetic activation has been attentively associated
with hyperinsulinemia, hyperleptinemia increased non-esterified
free fatty acids, inflammation, and obesity among others, however
the precise mechanisms remain to be unequivocally elucidated
(Lambert et al., 2010).
INSULIN-INDUCED SYMPATHETIC OVERACTIVATION
It is known since the early 80’s that insulin stimulates sympa-
thetic nerve activity (Rowe et al., 1981) and, more recently, it
has been shown that this stimulation occurs at blood insulin
concentrations within the physiological range (Hausberg et al.,
1995). In fact, the relationship between hyperinsulinemia and the
increased sympathetic nerve activity lead Landsberg to propose in
1986 a causal relationship between metabolic disturbances, such
as insulin resistance and dyslipidemia, and overactivation of the
SNS (Landsberg, 1986).
In the last decades several reports were published, both in
animals and in humans, supporting the hypothesis that insulin
increases sympathetic nerve activity. In humans insulin has been
shown to increase muscle sympathetic nerve activity (MSNA)
(Anderson et al., 1991; Scherrer et al., 1993; Vollenweider et al.,
1993) as well as norepinephrine levels (Anderson et al., 1991;
Lambert et al., 2010) in euglycemic conditions. The MSNA
response observed in response to insulin administration is both
gradual (Anderson et al., 1991; Scherrer et al., 1993; Vollenweider
et al., 1993, 1994; Banks, 2004) and sustained because MSNA
remains increased even after plasma insulin levels return to base-
line (Anderson et al., 1991; Scherrer et al., 1993; Vollenweider
et al., 1993, 1994; Banks, 2004). In rats and dogs, insulin infusion
also increases sympathetic nerve activity along with an increase
in plasma norepinephrine levels (Liang et al., 1982; Tomiyama
et al., 1992). However, the discovery that insulin infusion did
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not increase sympathetic nerve activity in the skin in humans
(Berne et al., 1992) and also that graded increases in plasma
insulin failed to significantly increase renal or adrenal sympa-
thetic activity in rats though leading to increased lumbar SNS
activity, lead to the hypothesis that hyperinsulinemia produces
regionally non-uniform increases in sympathetic nerve activ-
ity (Morgan et al., 1993). Also, while some authors claim that
the relationship between insulin concentrations and sympathetic
nerve activity is dose-dependent (Anderson et al., 1991; Berne
et al., 1992), others have shown that this relationship is not
apparent (Vollenweider et al., 1993, 1994) attributing this effect
to a saturation of the receptors needed for insulin to cross the
blood brain barrier (Banks et al., 1997; Dampney, 2011). The
slow rise and fall in MSNA produced by hyperinsulinemia would
be explained by the time insulin needs to cross the blood brain
barrier (Banks, 2004).
As reviewed previously, our group demonstrated that insulin
is capable of stimulating the CB eliciting a hyperventilatory
response (Ribeiro et al., 2013) (Figure 2). These results are in
accordance with the recent findings by Limberg et al. (2014)
where hyperoxic silencing of carotid chemoreceptors reduced
MSNA in hyperinsulinemic conditions, suggesting that the CB
also mediates insulin-dependent sympathoexcitation in humans
(Limberg et al., 2014).
THE ROLE OF CAROTID BODY IN METABOLIC DYSFUNCTION
SNS activation is implicated in the pathogenesis of metabolic dis-
eases and in the specific components of the metabolic syndrome,
such as insulin resistance, hypertension, dyslipidemia and obe-
sity (Kahn and Flier, 2000; Esler et al., 2006; Tentolouris et al.,
2006; Mancia et al., 2007). The idea that sympathetic hyper-
activity contributes to the development of insulin resistance is
not new (Defronzo, 1981), although the mechanisms involved in
the association between sympathetic nerve activity and insulin
resistance (Egan, 2003; Tentolouris et al., 2006; Tsioufis et al.,
2007, 2011), are complex and not clearly understood, and sev-
eral questions remain unanswered, including how is promoted
the sustained activation of the SNS that characterizes metabolic
diseases. Our group has recently proposed that the CB is the com-
mon link between sympathetic nerve activity, insulin resistance
and hypertension (Ribeiro et al., 2013) (Figure 5). The CBs con-
tribute to regulate blood pressure and cardiac performance via
SNS activation (Marshall, 1994) and through an increased sym-
pathetic drive, the CB directly activates the adrenals and increases
the sympathetic vasoconstrictor outflow to muscle, splanchnic,
and renal beds (Marshall, 1994; Cao and Morrison, 2001; Schultz
et al., 2007). Therefore, we have hypothesized that an overacti-
vation of the CB contributes to the genesis of insulin resistance,
core pathological feature of metabolic disorders as type 2 diabetes
or the metabolic syndrome. In fact, we have shown that animal
models of diet-induced prediabetes develop an overactivation of
the CB; measured as an increased spontaneous ventilation as well
as increased respiratory responses to ischemic hypoxia; increased
hypoxia-evoked release of dopamine and increased expression of
tyrosine hydroxilase (Ribeiro et al., 2013). This overactivation of
the CB results in an increase in SNS activity, measured as circu-
lating CAs and the adrenal medulla CAs content (Figure 3), and
FIGURE 5 | Schematic representation of carotid body involvement in
the development of insulin resistance through an increase in
sympathetic nervous system activity. Overactivation of the carotid body
caused by hyperinsulinemia and/or by chronic intermittent hypoxia
originates an increase in sympathetic nervous system activity that
promotes insulin resistance, hypertension, and probably dyslipidemia.
in an reduction in insulin sensitivity (Figure 4) (Ribeiro et al.,
2013). All these characteristic features of metabolic diseases were
prevented by CSN resection (Ribeiro et al., 2013) meaning that
the CB is primordial in controlling peripheral insulin sensitiv-
ity and that CB dysfunction is involved in the genesis of these
disturbances.
LINKING OBSTRUCTIVE SLEEP APNEA WITH METABOLIC
DYSFUNCTION
OBSTRUCTIVE SLEEP APNEA
Obstructive sleep apnea (OSA) is the most common form of
sleep disorder. It is characterized by repetitive collapse of the
pharyngeal airway during sleep, which generally requires arousal
to re-establish airway patency and resume breathing (Pillar and
Shehadeh, 2008). Upper airway obstruction can result in either
absent (apneas) or reduced (hypopneas) ventilation (Dempsey
et al., 2010), despite persisting respiratory efforts, such that
ventilatory requirements are not met. Consequently, hypox-
emia and hypercapnia develop, which further stimulate respira-
tory effort. However, without spontaneous airway opening, the
increased drive is ineffective to increase ventilation. Therefore,
the apnea/hypopnea typically continues until the patient arouses
from sleep and ends the obstruction. Following airway re-
opening, hyperventilation occurs to reverse the blood gas distur-
bances that developed during the respiratory event. The patient
then returns to sleep and another obstruction develops (Eckert
et al., 2009). The repetitive nature of these events results in
the excessive daytime sleepiness (Punjabi et al., 1999), fatigue
and neurocognitive dysfunction (Kim et al., 1997). Patients
with OSA are classically characterized by the apnea-hypopnea
index in mild OSA (≥5 and <15 events/hour), moderate OSA
(≥15 and <30 events/hour), and severe OSA (≥30 events/hour)
(Kapur, 2010). OSA of at least mild severity (five or more
events per hour of sleep) affects 5–20% of the general popu-
lation (Young et al., 1993, 2002) with a prevalence of 17–24%
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in men and 5–9% in women, and a tendency to even out after
the menopause (Young et al., 1993; Bixler et al., 1998, 2001).
The higher risk factors associated with OSA are age, male gen-
der, and high body mass index. and this sleep disturbance is also
linked to increased risk of hypertension, insulin resistance, glu-
cose intolerance, type 2 diabetes, dyslipidemia, atherosclerosis
and non-alcoholic fatty liver disease (Nieto et al., 2000; Newman
et al., 2001; Punjabi et al., 2004; Drager et al., 2005; Reichmuth
et al., 2005; Pulixi et al., 2014). The most effective and well-
studied treatment for OSA is continuous positive airway pressure
(CPAP) devices, which maintain upper airway patency during
sleep, promote sleep continuity and significantly improve sub-
jective and objective measures of daytime sleepiness (Patel et al.,
2003).
The association between OSA and hypertension is well estab-
lished (see Wolf et al., 2010 for a review). Bixler et al. (2000)
demonstrated that OSA was independently associated with hyper-
tension, both in men and women, being this relationship
strongest in young subjects and proportional to the severity of
the disease. The underlying mechanisms of OSA-induced hyper-
tension are not completely understood, however it has been
demonstrated that sympathetic activation plays a central role in
the pathophysiological process. OSA patients, exhibit elevated
blood pressure and elevated muscle sympathetic tone, as well
as increased plasma CAs, an effect that diminishes with CPAP
treatment (Somers et al., 1995; Kara et al., 2003). This high sym-
pathetic drive is present even during daytime wakefulness when
subjects are breathing normally and both arterial oxygen satura-
tion and carbon dioxide levels are also normal (Kara et al., 2003;
Narkiewicz and Somers, 2003). It was suggested that intermittent
hypoxia resulting from apneas is the primary stimulus for evok-
ing sympathetic excitation (Prabhakar et al., 2007, 2012) and that
hypercapnia that occurs during apneas and even apnea, by itself,
also contribute to sympathetic excitation (Prabhakar and Kumar,
2010; but see Lesske et al., 1997). Since the CB is the primary
sensor for hypoxia and the ensuing reflex activates sympathetic
nerve activity and elevates blood pressure (Lesske et al., 1997;
Prabhakar and Kumar, 2010), it was suggested that CB overac-
tivation by CIH produced by apneas would result in an increased
sympathetic activity and hypertension. In fact, the surgical den-
ervation of the CB prevented the increase in mean arterial blood
pressure induced by CIH, as well as the adrenal demedullation
and the chemical denervation of the peripheral SNS by 6-hydroxy
dopamine (Lesske et al., 1997). The involvement of an increased
sympatho-adrenal tone in CIH induced-hypertension was also
suggested by the finding that acute hypoxia in CIH animals
evoked the release of CAs from ex vivo adrenal medulla, an effect
that is absent in controls, suggesting that direct activation adrenal
medulla may account for the increase in blood pressure and
plasma CAs seen in CIH animals (Kumar et al., 2006). In addi-
tion to the sympathetic tone, endothelial dysfunction, oxidative
stress and inflammation have been proposed as potential mech-
anisms involved in the onset of the hypertension (see Gonzalez
et al., 2012). However, evidence for a unique pathogenic mech-
anism has been difficult to establish in OSA patients because of
concomitant co morbidities (Iturriaga et al., 2009; Del Rio et al.,
2012).
CHRONIC INTERMITTENT HYPOXIA: LINKING CAROTID BODY AND
OBSTRUCTIVE SLEEP APNEA
Chronic intermittent hypoxia (CIH), characterized by cyclic
hypoxic episodes of short duration followed by normoxia, is a
characteristic feature of OSA. The CB has been proposed to medi-
ate the reflex increase in sympathetic activity and blood pressure
associated with OSA due to CIH (Narkiewicz et al., 1999). In
fact, several studies have demonstrated an increase in periph-
eral CB drive in OSA subjects. This increased CB peripheral
drive was reflected by enhanced ventilatory and cardiovascular
reflex responses induced by acute hypoxia (Somers et al., 1995;
Narkiewicz et al., 1999) and also by an increase in basal tidal
volume (Loredo et al., 2001). In a pioneer study, Fletcher et al.
(1992a) demonstrated that 5 weeks of CIH induced an eleva-
tion of blood pressure in rats both during exposure to hypoxia
and subsequently. In a succeeding publication, the same authors
described that bilateral CB denervation prevented the develop-
ment of hypertension in rats exposed to CIH for 35 days (Fletcher
et al., 1992b), indicating that CB chemoreceptors are fundamen-
tal for the progression of CIH induced-hypertension. Consistent
with these findings it was also demonstrated that CB denervation
prevented the CIH-induced sympathetic activation (Prabhakar
et al., 2005). In the last decade several reports have strengthened
the idea that CIH resulting from sleep-disordered breathing leads
to an overactivation of the CB, manifested by its increased sensi-
tivity to hypoxia (Rey et al., 2004; Prabhakar et al., 2007; Peng
et al., 2009). The recording of CSN discharge in vitro and in
situ showed that exposure of animals to CIH increases the basal
CSN discharge and enhances the chemosensory response to acute
hypoxia (Peng et al., 2003; Rey et al., 2004; Gonzalez-Martín et al.,
2011). Furthermore, Peng et al. (2003) demonstrated that CIH
induces a CSN chemosensory long-term facilitation character-
ized by progressive increase in CSN activity with each hypoxic
episode, remaining the baseline activity elevated approximately
during 60 min after the last acute hypoxic stimuli. These authors
have also suggested that, since the increase in CB sensory activ-
ity triggers sympathetic nerve discharge and an increase in blood
pressure, sensory long-term facilitation contributes to the per-
sistent increase in SNA and blood pressure that is observed in
recurrent apnea patients (Peng et al., 2003). Peng et al. (2003)
also found that when CIH-exposed rats were re-exposed to nor-
moxia, the long-term facilitation and the augmented hypoxic
ventilatory response was reversed. The reversible nature of the
CB responses to CIH might explain why CPAP therapy reverses
the adverse cardio-sympathetic effects in OSA patients (Kara
et al., 2003). Also, CIH has no significant effect on CB weight
(Obeso et al., 2012) nor morphology, as CIH did not produce
significant differences in the total volume of the CB, number
of glomus cells or glomus cell volume (Peng et al., 2003). The
mechanisms underlying the CB overactivation induced by CIH
are not well understood, with this effect being attributed to
increased levels of endothelin-1 (Rey et al., 2006) and to reac-
tive oxygen species (ROS) in the CB (Peng et al., 2003, 2009);
however local expression of chemosensory modulators, like nitric
oxide, and pro-inflammatory cytokines in the CB may have differ-
ent temporal contribution to the CB chemosensory potentiation
induced by CIH (Prabhakar et al., 2005; Del Rio et al., 2011).
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Nevertheless, the possibility that alterations in the storing capac-
ity and dynamics of possibly several neurotransmitter systems
(e.g., CAs) (Gonzalez-Martín et al., 2011) cannot be excluded and
changes in the density and/or affinity of their receptors in the sen-
sory nerve endings could account for the overactivation of the CB
seen in CIH.
OBSTRUCTIVE SLEEP APNEA, CHRONIC INTERMITTENT HYPOXIA, AND
METABOLIC DYSFUNCTION
It is now consensual that OSA is independently associated with
metabolic syndrome, which incorporates visceral obesity, hyper-
tension, glucose intolerance, insulin resistance, and dyslipidemia
(Bonsignore et al., 2013). Several studies have reported that
metabolic syndrome is highly prevalent in OSA patients, with
rates between 50 and >80% (Bonsignore et al., 2013). The indica-
tion of a relationship between OSA and the various pathological
features of the metabolic syndrome, particularly insulin resis-
tance, is recent when compared with the considerable body of
evidence indicating that OSA can independently contribute to
the development of sustained daytime hypertension. One of the
earliest studies that showed that OSA is independently asso-
ciated with insulin resistance was the performed by Ip et al.
(2002), where the degree of insulin resistance was matched with
body mass index and severity of OSA among 185 patients.
Through a multiple linear regression, the authors found that obe-
sity was the primary determinant of insulin resistance, but the
patient’s apnea-hypopnea index and minimal arterial O2 satura-
tion were also significantly contributors (Ip et al., 2002). In 2004
a large epidemiological study directly assessed OSA prevalence by
polysomnography and measured glucose and insulin levels under
fasting and after an oral glucose tolerance test in a subset of 2656
subjects from the Sleep Heart Health Study. The authors showed
that subjects with mild or moderate to severe OSA had elevated
fasting glucose and impaired oral glucose tolerance (Punjabi et al.,
2004). Also, they demonstrated that the effect of OSA on glu-
cose intolerance was independently associated with age, gender,
body mass index and waist circumference (Punjabi et al., 2004). In
another study, Punjabi and Beamer (2009), performed an intra-
venous glucose tolerance test in 118 non-diabetic subjects and
found that the apnea-hypopnea index and the severity of noctur-
nal oxyhemoglobin desaturation were associated with decreased
insulin sensitivity and pancreatic β-cell dysfunction, the effect
being independent of age, sex and percent body fat (Punjabi and
Beamer, 2009).
As expected by its association with insulin resistance, OSA
may also be a risk factor for the development of type 2 diabetes,
according to two large prospective studies. These two studies
showed that regular snoring is associated with a 2- to 7-fold risk
for type 2 diabetes over a period of 10 years (Elmasry et al.,
2000; Al-Delaimy et al., 2002). Since snoring is not a clinical diag-
nostic for OSA, in a longitudinal study, Reichmuth et al. (2005)
analyzed the data from 1387 subjects in the Wisconsin Sleep
Cohort and examining the association between OSA, diagnosed
by polysomnography, and the development of type 2 diabetes.
Comparable to previous cross-sectional studies, a positive associ-
ation between clinically diagnosed OSA and type 2 diabetes, after
adjustment for age, sex, and waist girth was shown (Reichmuth
et al., 2005). However, in a follow-up study of 978 subjects, the
odds ratio for developing type 2 diabetes within a 4 years period
for those with an apnea-hypopnea index of >15 events/hour did
not reach statistical significance after adjustment for waist girth
(Reichmuth et al., 2005). Since it is well described that insulin
resistance precedes in approximately 10–15 years the develop-
ment of type 2 diabetes (Nathan, 2002), the limitation of this
work may be related with the duration of follow-up that was only
4 years. Therefore, further longitudinal studies would be neces-
sary to fully examine the role of OSA in the development of type
2 diabetes.
The link between OSA and metabolic dysfunction was also
sustained by the results obtained by Babu et al. (2005) showing
that CPAP treatment for 3 months decreased postprandial glucose
levels and glycated hemoglobin in type 2 diabetes patients with
OSA, being the decrease higher when CPAP was used for more
than 4 h per night (Babu et al., 2005). Also, Harsch et al. (2004a)
observed an increase in insulin sensitivity, assessed through a
hyperinsulinemic-euglycemic clamp, in type 2 diabetes patients
after 3 months of effective CPAP treatment. In another study
performed by Harsch et al. (2004b), in OSA patients without
type 2 diabetes, it was observed that CPAP treatment increased
insulin sensitivity within 2 days of therapy, with further improve-
ments occurring at the 3 months follow-up. In contrast with the
reported beneficial effects of CPAP on glucose metabolism and
insulin resistance in OSA patients, some studies demonstrated
that CPAP treatment for 3 or 6 months did not improve fasting
glucose or insulin plasma levels (Ip et al., 2000). These differences
among studies may be related with the treatment duration, lack of
a control group, insufficient statistical power and absence of data
on CPAP compliance.
The exact mechanism for the pathological changes that occur
in glucose metabolism and insulin action in OSA patients is not
completely understood. It is possible that multiple interrelated
factors contribute to the complex interactions between OSA, obe-
sity and glucose control. OSA is intrinsically associated with CIH
and sleep loss due to sleep fragmentation, and both induce insulin
resistance (Tasali et al., 2008). Recently, a lot of research has been
published devoted to the study CIH and metabolic dysfunction
in rodents however some of the data obtained is not consen-
sual. It has been shown that mice exposed during 30 days to
CIH exhibited elevated levels of fasting plasma insulin but com-
parable glucose levels and higher homeostasis model assessment
(HOMA) index, indicating insulin resistance, an effect that was
attributed to a pancreatic β-cell dysfunction (Wang et al., 2013).
These results were sustained by the recent work of Gonzalez
group where they observe that 15 days of CIH in rats induce
insulin resistance, assessed by the HOMA index without affect-
ing fasting glucose plasma levels and glucose tolerance (Olea
et al., 2014). These findings obtained in mice and rats contrast
with the recent publication by Shin and co-workers where they
show that 4/6 weeks of CIH in mice increased fasting blood glu-
cose, baseline hepatic glucose output but not insulin sensitivity
measured through a hyperinsulinemic euglycemic clamp (Shin
et al., 2014). These effects being mediated by the CB as CSN
denervation prevented the CIH-induced hyperglycemia and the
increase in hepatic glucose output (Shin et al., 2014). Whereas the
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differences obtained in several metabolic parameters, like fasting
glycemia, can be due to distinct species studied as well as to the
different CIH paradigms, we must refer that HOMA index is a
human index, an must not be used as the only index to assess
insulin resistance in rodents.
Several intermediate mechanisms have been proposed to
explain the pathological alterations in glucose metabolism in
OSA: increased sympathetic activation, deregulation of the
hypothalamus-pituitary axis and generation of ROS (Tasali
et al., 2008). In addition, pancreatic β-cells are highly sensi-
tive to hypoxia, and the subsequent shift to anaerobic glycolytic
metabolism favors insulin resistance (Pallayova et al., 2011).
Also, it was recently shown that mice exposed to 30 days CIH
exhibited pancreatic β-cell dysfunction, manifested by impaired
glucose-stimulated insulin secretion and increased mitochon-
drial ROS (Wang et al., 2013), which may contribute to the
development of type 2 diabetes among sleep apnea patients.
Finally, the oxidative status and activation of inflammatory path-
ways can also contribute to deregulation of metabolism (Tasali
et al., 2008). It has been recently shown that 15 days to CIH
in rats induce an oxidative status manifested by an increase
in lipid peroxides and diminished activities of superoxide dis-
mutases, an inflammatory status characterized by augmented
C-reactive protein and nuclear factor kappa-B activation and a
sympathetic hyperactivity assessed by plasma and renal artery
CA levels and synthesis rate (Olea et al., 2014). Also, the same
authors have shown that, as expected, the combination of CIH
and obesity worsened the alterations observed (Olea et al.,
2014).
Obesity is considered a major risk factor for the development
and progression of OSA. It is estimated that 40% of obese individ-
uals have OSA; consequently approximately 70% of individuals
with OSA are obese (Vgontzas et al., 2000; Daltro et al., 2007).
One possible mechanisms by which obesity may worsen OSA is
due to fat deposition at specific sites of the body, namely in the
upper airways. In fact, fat deposition in the tissues surround-
ing the upper airway appears to result in a smaller lumen and
increased collapsibility of the upper airway, predisposing to apnea
(Shelton et al., 1998; Schwab et al., 2003). This increase in fat
deposition next to the upper airways can be found even in non-
obese subjects with OSA (Mortimore et al., 1998). Fat deposits
around the thorax (truncal obesity) also reduce chest compli-
ance and functional residual capacity, and may increase oxygen
demand (Naimark and Cherniack, 1960). Another fat depot that
can contribute to OSA is visceral fat. Visceral obesity is common
in subjects with OSA and is closely related with an increase in
apnea index (Shinohara et al., 1997), Since obesity is positively
correlated with OSA, weight loss and weight gain prevention offer
a successful therapeutic approach to reduce the occurrence and
the severity of OSA and its related mortality. In a longitudinal
study, Peppard et al. (2000) showed that a 10% of weight loss
predicted a 26% decrease in the apnea-hypopnea index, which
suggest that even a modest weight loss may be effective in man-
aging OSA and reducing new occurrence of OSA. Furthermore,
CPAP treatment for 6 months led to visceral fat loss even if
subjects did not lose weight (Chin et al., 1999). Short sleep frag-
mentation is associated with decreased levels of leptin, a hormone
that lowers food intake, increases energy expenditure (Friedman
and Halaas, 1998) and is secreted in proportion to body fat stores
(Considine et al., 1996). In OSA subjects, several studies reported
increased leptin levels compared to weight-matched control (Ip
et al., 2000; Vgontzas et al., 2000), which correlated with OSA
severity (Ip et al., 2000), and decreased after CPAP treatment
(Chin et al., 1999).
Although obesity is the primary risk factor for OSA this disease
also affects lean subjects, as Pamidi et al. (2012) demonstrated
that young lean men, free of cardiometabolic disease, the presence
of OSA is associated with IR and compensatory hyperinsuline-
mia to maintain normal glucose homeostasis (Pamidi et al.,
2012). Therefore, from this study we can conclude that OSA may
increase the risk of type 2 diabetes independently of traditional
cardiometabolic risk factors. In the Sleep Heart Study (Seicean
et al., 2008), a large community-based cohort of older individu-
als (>65 years of age), the presence of OSA was associated with a
higher prevalence of prediabetes and occulted type 2 diabetes in
the non-overweight group. Furthermore, the effect of CPAP treat-
ment may be different between obese and non-obese subjects.
Harsch et al. (2004b) showed that the improvement in insulin
sensitivity was much smaller in obese subjects than in non-obese
subjects, suggesting that in obese individual’s insulin sensitivity is
mainly determined by obesity and, to a smaller extent, by sleep
apnea.
Obesity is known to be strongly associated with metabolic dys-
function, and that contributes to insulin resistance and glucose
intolerance (Landsberg, 1996, 2001), nevertheless metabolic dys-
function can be present in lean OSA subjects (Pamidi et al., 2012).
In CIH rodent models metabolic dysfunction is present with-
out the obesity component (Carreras et al., 2012; Fenik et al.,
2012; Wang et al., 2013; Shin et al., 2014), as it was described
that animals submitted to CIH gain less weight (Carreras et al.,
2012) or the similar weight (Olea et al., 2014) in comparison
with controls. Also, the amounts of perirenal and epididymal
fat found in CIH animals was similar to those found in con-
trols (Olea et al., 2014). Taken together these results show that in
OSA, obesity is not the only factor that contributes to metabolic
dysfunction. The involvement of CB has been recently proposed
as one of the links between CIH and sympathetic overactivity
and metabolic dysfunction, since CB denervation prevents CIH-
induced fasting hyperglycemia, although CB denervation was
incapable of prevent insulin resistance (Shin et al., 2014), sug-
gesting that other mechanisms can account for the CIH induced-
insulin resistance. In fact, little is known regarding the molecular
mechanisms behind this relationship, with the reduction of Glut4
metabolic fraction in skeletal muscle in CIH animals being the
only mechanism described (Carreras et al., 2012). Therefore,
detailed studies on the molecular mechanisms of insulin action
in insulin-sensitive tissues will contribute enormously to bet-
ter understand the paradigm of CIH-induced insulin resis-
tance, and so the relationship between OSA and metabolic
dysfunction.
FUTURE PERSPECTIVES
In the last couple of years, several reports of non-classical roles
of the CB on glucose homeostasis and metabolic regulation have
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been published, contributing to launch the CB as a putative ther-
apeutic target for the treatment of endocrine diseases. Our group
has been actively involved in the process and recently we described
that chronic CB overstimulation is implicated in the etiology of
diet-induced insulin resistance (Ribeiro et al., 2013). We have
also described that surgical resection of the CSN prevents the
development of dysmetabolic changes induced by hypercaloric
treatments in rats (Ribeiro et al., 2013), an observation that con-
tributed to strengthen that CB blockade/modulation represents a
novel and unexploited therapeutic approach.
Besides the surgical resection of the CB, its overactivation can
also be prevented pharmacologically with an old, well-studied
and very safe drug: caffeine. Sustained caffeine administration
prevents the development of hypertension, impaired glucose
tolerance and insulin resistance in prediabetes animal models
(Conde et al., 2012b; Panchal et al., 2012). The protective effect
of chronic caffeine administration was accompanied by preven-
tion of weight gain and decreased visceral fat in obese animals;
however caffeine also exerted its positive metabolic effects in
lean models of insulin resistance and hypertension independently
of weight loss (Conde et al., 2012b). A putative mechanism
related with blockade of adenosine receptors in the CBs and,
therefore, with the inhibition of CB-mediated sympathetic over-
activation by chronic caffeine administration has been proposed
as a paradigm shift to explain the reduction of insulin resistance,
blood pressure and type 2 diabetes risk induced by sustained
consumption of this xanthine (Conde et al., 2012b,c; Ribeiro
et al., 2013). The translation of these promising results into
human medicine, namely through controlled clinical trials is still
lacking—but the epidemiological data available strongly indicate
that caffeine should integrate a normal healthy diet, and actually
contribute to decrease the incidence of type 2 diabetes and obesity
in high-risk populations (van Dam and Hu, 2005; Bhupathiraju
et al., 2014).
Another way of modulating CB activity would be to directly
target its effector, the SNS. The SNS may also represent a putative
target to treat metabolic diseases related with insulin resistance,
particularly if modulated regionally in classical insulin-target tis-
sues like the skeletal muscle. This pinpoint modulation may be
achieved through the use on Bioelectronic Medicines, electronic
devices connected to individual peripheral nerve fibers, aiming to
correct pathological electrical patterns and restore health (Famm
et al., 2013). This new area of therapeutics is emerging right
now, with the promise and ambitious goal of modulating specific
peripheral nerves. Due to the important role the CBs seem to play
in both the metabolic and hemodynamic control, they represent
a natural candidate for Bioelectronic Medicines to be tested in a
not so distant future.
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